|
rs156697
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Bladder cancer risk overall was associated with GSTO2 Asn142Asp (homozygous; OR=1.4; 95% CI: 1.0-1.9; P for trend=0.06) and GSTZ1 Glu32Lys (homozygous; OR=1.3; 95% CI: 0.9-1.8; P for trend=0.06).
|
22306368 |
2012 |
|
rs1484761909
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Bladder cancer risk overall was associated with GSTO2 Asn142Asp (homozygous; OR=1.4; 95% CI: 1.0-1.9; P for trend=0.06) and GSTZ1 Glu32Lys (homozygous; OR=1.3; 95% CI: 0.9-1.8; P for trend=0.06).
|
22306368 |
2012 |
|
rs758057623
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Bladder cancer risk overall was associated with GSTO2 Asn142Asp (homozygous; OR=1.4; 95% CI: 1.0-1.9; P for trend=0.06) and GSTZ1 Glu32Lys (homozygous; OR=1.3; 95% CI: 0.9-1.8; P for trend=0.06).
|
22306368 |
2012 |
|
rs7975
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Bladder cancer risk overall was associated with GSTO2 Asn142Asp (homozygous; OR=1.4; 95% CI: 1.0-1.9; P for trend=0.06) and GSTZ1 Glu32Lys (homozygous; OR=1.3; 95% CI: 0.9-1.8; P for trend=0.06).
|
22306368 |
2012 |
|
rs1476413
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Bladder cancer cases were also 60% less likely to be homozygotes for the A allele in rs1476413 in MTHFR compared to controls (OR = 0.40; 95% CI = 0.18-0.88).
|
22747749 |
2012 |
|
rs798766
|
|
|
0.770 |
GeneticVariation |
BEFREE |
rs798766 is associated with increased risk of bladder cancer, and no ethnic difference was found.
|
28655970 |
2017 |
|
rs2304277
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A 3' untranslated region polymorphism rs2304277 in the DNA repair pathway gene OGG1 is a novel risk modulator for urothelial bladder carcinoma.
|
29139108 |
2018 |
|
rs1051740
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A comprehensive systematic review and meta-analysis was performed of available studies on these two polymorphisms and cancer risk published up to November 2010, consisting of 84 studies (31144 cases and 42439 controls) for Tyr113His and 77 studies (28496 cases and 38506 controls) for His139Arg primarily focused on lung cancer, upper aerodigestive tract (UADT) cancers (including oral, pharynx, larynx and esophagus cancers), colorectal cancer or adenoma, bladder cancer and breast cancer.
|
21445251 |
2011 |
|
rs2234922
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A comprehensive systematic review and meta-analysis was performed of available studies on these two polymorphisms and cancer risk published up to November 2010, consisting of 84 studies (31144 cases and 42439 controls) for Tyr113His and 77 studies (28496 cases and 38506 controls) for His139Arg primarily focused on lung cancer, upper aerodigestive tract (UADT) cancers (including oral, pharynx, larynx and esophagus cancers), colorectal cancer or adenoma, bladder cancer and breast cancer.
|
21445251 |
2011 |
|
rs2228001
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A meta-analysis was performed to examine the association between XPC Lys939Gln polymorphism and susceptibility to bladder cancer (BC).
|
23269608 |
2013 |
|
rs1799983
|
|
|
0.030 |
GeneticVariation |
BEFREE |
A significant association for NOS3 Glu298Asp heterozygotes genotypes and T allely were found between healthy controls and bladder cancer, respectively (p<0.001: p=0.002).
|
23621215 |
2013 |
|
rs1800371
|
|
|
0.020 |
GeneticVariation |
BEFREE |
A significant association was found with p53 codon 248 polymorphism and BC risk whereas p53 codon 11 and p53 Pro47Ser polymorphism showed no association with BC risk.
|
22101376 |
2011 |
|
rs2839698
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A significantly decreased risk of bladder cancer was found for the rs2839698 TC genotype (odds ratio [OR], 0.60; 95% confidence interval (95%CI), 0.36-0.99), but not for CC homozygotes.
|
18262338 |
2008 |
|
rs9642880
|
|
|
0.760 |
GeneticVariation |
BEFREE |
A single nucleotide polymorphism of MYC rs9642880 (G>T) at the 8q24.1 locus is thought to be associated with bladder cancer risk based on the results of genome-wide association studies, but the results remain inconclusive.
|
26600535 |
2015 |
|
rs16901904
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A two-stage case-control study was conducted to assess the association between four tagging SNPs (i.e., rs4871771, rs1902432, rs16901904 and rs710886) and bladder cancer risk.
|
28627442 |
2017 |
|
rs2295080
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Additionally, mTOR rs2295080 variant notably increased the risk of BC (OR=2.25, 95 % CI=1.50-3.38, p<0.0001, GT vs GG; OR=4.75, 95 % CI=2.80-8.06, p<0.0001, TT vs GG; OR=3.10, 95 % CI=2.34-4.10, p<0.0001, T vs G).
|
29383014 |
2018 |
|
rs709816
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Additionally, positive associations were found for rs709816 with bladder cancer (OR(adj) = 4.2, 95% CI: 1.4, 12) and rs1063054 with lung cancer (OR(adj) = 1.6, 95% CI: 1.0, 2.3).
|
20478923 |
2010 |
|
rs1063054
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Additionally, positive associations were found for rs709816 with bladder cancer (OR(adj) = 4.2, 95% CI: 1.4, 12) and rs1063054 with lung cancer (OR(adj) = 1.6, 95% CI: 1.0, 2.3).
|
20478923 |
2010 |
|
rs1799864
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Additionally, the combination of CCR2 V64I and CCR5 Δ32 (i.e., GG-wt/Δ32) was found to be associated with BC risk.
|
22982413 |
2012 |
|
rs763059810
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Additionally, the combination of CCR2 V64I and CCR5 Δ32 (i.e., GG-wt/Δ32) was found to be associated with BC risk.
|
22982413 |
2012 |
|
rs1799793
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Among four DNA repair gene polymorphisms, the OGG1 326 Ser/Cys and XPD 312 Asp/Asn heterozygous genotypes might be recognized as potential genetic markers modifying susceptibility to bladder cancer in Belarus.
|
25089939 |
2014 |
|
rs1052133
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Among four DNA repair gene polymorphisms, the OGG1 326 Ser/Cys and XPD 312 Asp/Asn heterozygous genotypes might be recognized as potential genetic markers modifying susceptibility to bladder cancer in Belarus.
|
25089939 |
2014 |
|
rs8034191
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Among NHW, a significant association was found between rs8034191 and bladder cancer which persisted after adjustment for cigarette smoking status, number of cigarettes smoked per day and number of years of smoking (per C allele OR = 1.26; 95% CI, 1.04-1.54; P = 0.017).
|
21081471 |
2011 |
|
rs20417
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Among the six polymorphic sites examined, only the Cox-2 promoter G-765C (rs20417) genotypes were positively associated with bladder cancer risk (p=0.0102).
|
24324075 |
2013 |
|
rs41277434
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Among the three polymorphic sites examined, the genotypes of EZH2 rs887569 (C to T), but not rs41277434 (A to C) or rs3757441 (T to C), were positively associated with bladder cancer risk (p for trend =0.0146).
|
27630289 |
2016 |